Abstract
Neovascularisation is the biological process of forming new blood vessels. Many conditions can initiate neovascularisation including trauma or chronic ischaemia produced by diseases such as diabetes. Neovascularisation proceeds through a series of steps beginning with destruction of the basement membrane surrounding the microvascular endothelial cells, which allows endothelial cells to extend cytoplasmic buds in the direction of chemotactic factors. Migrating endothelial cells elongate, divide and eventually form tube structures which join to form mature new capillaries.
Results of in vitro experiments, in vivo experiments, and clinical studies suggest that peptide growth factors can play key regulatory roles in each step of neovascularisation through both direct and indirect actions. At sites of vascular injuries, degranulating platelets release PDGF, IGF-I, EGF, and TGF-β. Macrophages and neutrophiles drawn into the ischaemic or injured areas synthesise and release TGF-α, TGF-β, and PDGF, and wounded endothelial cells secrete FGF. These peptide growth factors can stimulate migration, mitosis and differentiation of endothelial cells in culture and can induce neovascularisation in animal models. Clinical correlations suggest that peptide growth factors in the vitreous such as IGF-I and bFGF may promote diabetic retinopathy. As the biological mechanisms of neovascular growth factors become better understood, it may be possible to develop therapeutic approaches to selectively inhibit the peptide growth factors which regulate neovascular diseases.
Similar content being viewed by others
Article PDF
References
Folkman J and Klagsbrun M : Angiogenic factors. Science 1987, 235: 442–7.
Ashton N : Neovascularisation in ocular disease. Trans Ophthalmol Soc 1961, 81: 145–61.
Michaelson IC : The mode of development of retina vessels. Trans Ophthalmol Soc 1968, 68: 137–80.
Raymond L and Jacobsen B : Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous. Exp Eye Res 1982, 34: 267–86.
Lobb RR, Harper JW, Fett JW : Purification of heparin-binding growth factors. Analyt Biochem 1986, 154: 1–14.
Neufeld G and Gospodarowicz D : The identification and partial characterisation of the fibroblast growth factor receptor of baby hamster kidney cells. J Biolog Chem 1985, 260: 13860–8.
Gospodarowicz D, Massoglia S, Cheng J, Fujii DK : Effect of retina-derived basic and acidic fibroblast growth factor and lipoproteins on the proliferation of retina-derived capillary endothelial cells. Exp Eye Res 1986, 43: 450–76.
Gospodarowicz D, Bialecki H, Thakral T : The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res 1979, 28: 501–14.
McNeil PL, Muthukrishnan L, Warder E, D'Amore PA : Growth factors are released by mechanically wounded endothelial cells. J Cell Biol 1989, 109: 811–22.
Klagsburn M and Vlodavsky I : Biosynthesis and storage of basic fibroblast growth factor (bFGF) by endothelial cells: Implication for the mechanism of action of angiogenesis. Growth factors and other aspects of wound healing: Biological and clinical implications. New York, Alan R. Liss, Inc., 1988, 55–61.
de Juan E, Stefansson E, Ohiro A : Basic fibroblast growth factor stimulates 3H-thymidine uptake in retinal venular and capillary endothelial cells in vivo. Invest Ophthalmol Vis Sci 1990, 31: 1238–44.
Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L : Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990, 108: 869–72.
Schwarder JC, Hauri C, Zapf J, Froesch ER : Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: Dependence on growth hormone status. Endocrinol 1983, 113: 297–305.
Daughaday WH and Kipnis DM : The growth-promoting and anti-insulin actions of somatotropin. Recent Prog Horm Res 1966, 22: 49–93.
Zapf J, Schoenle E, Jagars G, Sand I, Grundwald J, Froesch ER : Inhibition of the action of nonsuppressible insulin-like activity on isolated rat fat cells by binding to its carriers protein. J Clin Invest 1979, 63: 1077–84.
Elgin RG, Busby WH, Clemmons DR : An insulin-like growth factor (IGF) binding protein enhances the biological reponse to IGF 1. Proc Natl Acad Sci USA 1986, 84: 3254–8.
Hintz RL and Liu F : Somatomedin plasma binding proteins. In: Pecile A, Muller EE, eds. Growth hormone and other biologically active peptides. Amsterdam: Excerpta Medica, 1980, 133–143.
Cohen KL and Nissley SP : The serum half-life of Somatomedin activity: Evidence for growth hormone dependency. Acta Endocrinol 1979, 83: 243–58.
Povoa G, Hall K, Collins VP : Studies on Somatomedin binding proteins: In: Muller EE, Cocch D. Advances in growth hormone and growth factor research, Berlin-Heidelberg Springer Verlag. 1989, 121–132.
D'Ercole AJ, Stiles AD, Underwood LE : Tissue concentrations of Somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 1984, 81: 935–9.
King GL, Goodman AD, Bosnex S, Moses A, Kahn CR : Receptors and growth promoting effects of insulin and IGF 1 on cells from bovine retinal capillaries and aorta. J Clin Invest 1985, 75: 1028.
Grant M, Jerdan J, Merimee TJ : Insulin-like growth factor-I modulates endothelial cell chemotaxis. J Clin Endocrin Metab 1987, 65: 370–1.
Grant MB and Gary C : Plasminogen activator production by Human retina endothelial cells of non-diabetic and diabetic origin. Invest Ophthalmol Vis Sci 1991, 32: 53–63.
Merimee TJ, Zapf J, Froesch ER : Insulin-line growth factors: Studies in diabetics with and without retinopathy. N Engl J Med 1983, 309: 527–30.
Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM : A two-year follow-up study of serum insulin-like growth factor-I in diabetes with retinopathy. Metabolism 1989, 38: 586–9.
Grant M, Burrell B, Fitzgerald C, Merimee TJ : Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascular-isation. Diabetes 1986, 35: 416–20.
Burgess AW : Epidermal growth factor and transforming growth factor α. Br Med Bull 1989, 45: 401–24.
Brown JP, Twardzik Dr, Marquardt H, Todaro J : Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature 1985, 313: 491–2.
Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ : Structure and function of human amphiregulin: A member of the epidermal growth factor family. Science 1989, 243: 1075–6.
Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG : Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987, 328: 820–3.
Coffey RJ, Derynck R, Wilcox JN, Bringman TS, Goustin AS, Moses HL, Pittelkow MR : Production and auto-induction of transforming growth factor α in human keratinocytes. Nature 1987, 328: 817–20.
Gospodarowicz D, Bialecki H, Thakral TK : The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res 1979, 28: 501–14.
Steward R, Nelson J, Wilson DJ : Epidermal growth factor promotes chick embryonic angiogenesis. Cell Biol Inter Reports 1989, 13: 957–65.
Schreiber AB, Winkler ME, Derynck R : Transforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor. Science 1986, 232: 1250–3.
Grotendorst GR, Soma Y, Takehara K, Charett M : EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regulation. J Cell Physiol 1989, 139: 617–23.
Fassio JB, Brockman EB, Jumblatt M, Greaton C, Henry JL, Geoghegan TE, Barr C, Schultz GS : Transforming growth factor alpha and its receptor in neural retina. Invest Ophthal Vis Sci 1989, 30: 1916–22.
Roberts AB and Sporn MB : The transforming growth factor-χs. In Piez KA and Sporn MB eds. Transforming growth facto-βs. New York: New York Academy of Sciences 1990, 1–6.
Lyons RM and Moses HL : Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990, 187: 467–73.
Lyons RM, Gentry LE, Purchio AF, Moses HL : Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 1990, 110: 1361–7.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS : Transforming growth factor type B: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci 1986, 83: 4167–71.
Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeier W : Inhibitory action of transforming growth factor β on endothelial cells. Proc Natl Acad Sci 1987, 84: 5600–04.
Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB : Transforming growth factor type β. Proc natl Acad Sci 1987, 84: 5788–92.
Rappolee DA, Mark D, Banda MJ, Webb Z . Wound macrophages express TGF-α and other growth factors in vivo. Analysis by mRNA phenotyping. Science 1988, 241: 708–12.
Orlidge-Antonelli A, Saunders KB, Smith SR, D'Amore PA : An activated form of transforming growth factor β is produced by co-cultures of endothelial cells and pericytes. Proc Natl Acad Sci 1989, 86: 4544–8.
Orlidge-Antonelli A, Smith SR, D'Amore PA : Influence of pericytes on capillary endothelial cell growth. Am Rev Respir Dis 1989, 140: 1129–31.
Moses HL, Tucker RF, Leof EB, Coffey RJ, Halper J, Shipley GD : Type-β transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells 1985, 3: 65–71.
Connor TB, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM : Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989, 83: 1661–6.
Merimee TJ : Diabetic retinopathy a synthesis of perspectives. N Eng J Med 1990, 322: 978–83.
Author information
Authors and Affiliations
Additional information
Supported in part by funds from NIH Grant EY05587, EY07739 and the Juvenile Diabetes Foundation.
Rights and permissions
About this article
Cite this article
Schultz, G., Grant, M. Neovascular growth factors. Eye 5, 170–180 (1991). https://doi.org/10.1038/eye.1991.31
Issue Date:
DOI: https://doi.org/10.1038/eye.1991.31
Keywords
This article is cited by
-
Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients
Eye (2023)
-
The impact of IGF-I, puberty and obesity on early retinopathy in children: a cross-sectional study
Italian Journal of Pediatrics (2019)
-
Semax-Induced Changes in Growth Factor mRNA Levels in the Rat Brain on the Third Day After Ischemia
International Journal of Peptide Research and Therapeutics (2016)
-
Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?
Journal of Cell Communication and Signaling (2011)
-
Elevated lipid peroxides induced angiogenesis in proliferative diabetic retinopathy
Journal of Ocular Biology, Diseases, and Informatics (2010)